Table 2. Estimation of the hazard ratio.
| Study | Survival analysis | HR estimation | Co-factors | Analysis results |
| Gazzaniga10 | recurrence-free | p value, event number (univariate) | − | not significant |
| Schultz52 | recurrence-free | absence of eligible data | − | significant |
| progression-free | p value, event number (univariate) | − | not significant | |
| cancer-specific | absence of eligible data | − | not significant | |
| Ku53 | recurrence-free | HR, 95% CI (multivariate) | age, sex, size, number, architecture, grade, T stage | significant |
| Schultz54 | recurrence-free | p value, event number (univariate) | − | significant |
| Yin55 | progression-free | HR, 95% CI (multivariate) | age, grade, T stage, grade and stage, ki67, BIRC5-C | significant |
| cancer-specific | HR, 95% CI (multivariate) | age, grade, T stage, grade and stage, ki67, BIRC5-C | significant | |
| Karam56 | recurrence-free | HR, 95% CI (multivariate) | grade, T stage, intravesical therapy | significant |
| progression-free | HR, 95% CI (multivariate) | grade, T stage, intravesical therapy | significant | |
| cancer-specific | HR, 95% CI (multivariate) | grade, T stage, intravesical therapy | not significant | |
| Pina-Cabral57 | recurrence-free | p value, event number (univariate) | − | significant |
| Skagias58 | recurrence-free | HR, 95% CI (multivariate) | grade, T stage | Significant |
| overall | HR, 95% CI (multivariate) | grade, T stage | not significant | |
| Weiss59 | recurrence-free | p value, event number (univariate) | − | significant |
| progression-free | p value, event number (univariate) | − | not significant | |
| cancer-specific | p value, event number (univariate) | − | not significant | |
| Gradilone11 | recurrence-free | HR, 95% CI (multivariate) | circulating tumor cell | not significant |
| Fristrup (Denmark)60 | progression-free | HR, 95% CI (multivariate) | cathepsin E, maspin, PIK1 | significant |
| cancer-specific | HR, 95% CI (multivariate) | cathepsin E, maspin, PIK1 | significant | |
| overall | HR, 95% CI (multivariate) | cathepsin E, maspin, PIK1 | significant | |
| Fristrup (validation)60 | progression-free | HR, 95% CI (multivariate) | cathepsin E, maspin, PIK1 | significant |
| Xi61 | progression-free | HR, 95% CI (multivariate) | grade, T stage, livin | significant |
| Shariat62 | recurrence-free | HR, 95% CI (multivariate) | Age, sex, grade, pT stage, N stage, surgical margin, LVI,concomitant CIC, ACH | significant |
| cancer-specific | HR, 95% CI (multivariate) | Age, sex, grade, pT stage, N stage, surgical margin, LVI,concomitant CIC, ACH | significant | |
| Als63 | overall | HR, 95% CI (multivariate) | visceral metastasis, emmprin | significant |
HR: hazard ratio, CI: confidence interval, BIRC5-C: cytoplasmic staining of survivin, LVI: lymphovascular invasion, CIS: carcinoma in situ, ACH: adjuvant chemotherapy.